- ROS1 is a receptor tyrosine kinase of the insulin receptor family, similar to ALK.
- ROS1 gene rearrangements are more likely found in younger patients (<50 years) and light/never smokers and associated with adenocarcinoma.1
- ROS1 has been included in the 2013 NCCN guidelines as a relevant biomarker in NSCLC, including showing response to ALK Inhibitor therapy.2
1. Bergethon K, Shaw AT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012:30:863-870.
2. NCCN Guidelines Version 2.2013